Epirubicin
Back to searchMolecule Structure
Scientific Name
Epirubicin
Description of the Drug
Epirubicin is an anthracycline topoisomerase II inhibitor used as an adjuvant to treating axillary node metastases in patients who have undergone surgical resection of primary breast cancer.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00445
http://www.drugbank.ca/drugs/DB00445
Brand Name(s)
Not Available
Company Owner(s)
Cipla Ltd, Fresenius Kabi Usa Llc, Mylan Laboratories Ltd, Hospira Inc, Actavis Totowa Llc, Ebewe Pharma Ges Mbh Nfg Kg, Hisun Pharmaceutical (Hangzhou) Co Ltd, Zennova Pharmaceuticals Chengdu Co Ltd, Impax Laboratories Inc, Hikma Pharmaceuticals Usa Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2311221 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL8582 | ||
PharmGKB | PA449476 | ||
Human Metabolome Database | HMDB0014588 | ||
DrugBank | DB00445 | ||
PubChem: Thomson Pharma | 14812446 | 14837077 | |
PubChem | 41867 | ||
NMRShiftDB | 60022164 | ||
LINCS | LSM-2078 | ||
Nikkaji | J81.933F | ||
BindingDB | 43839 | ||
EPA CompTox Dashboard | DTXSID0022987 | ||
DrugCentral | 1030 | ||
Metabolights | MTBLC47898 | ||
rxnorm | ELLENCE | EPIRUBICIN HYDROCHLORIDE | EPIRUBICIN |
KEGG Ligand | C11230 | ||
ChEBI | 47898 | ||
ZINC | ZINC000003938704 |